GRAIL, Inc.
GRAIL, Inc., a pioneering company in the field of early cancer detection, is headquartered in the United States. Founded in 2016, GRAIL has rapidly established itself as a leader in the biotechnology industry, focusing on innovative blood tests that aim to identify multiple types of cancer at their earliest stages. With a commitment to transforming cancer care, GRAIL's flagship product, Galleri™, utilises advanced genomic sequencing technology to detect cancer signals in the bloodstream, setting it apart from traditional screening methods. The company has achieved significant milestones, including partnerships with major healthcare providers and research institutions, enhancing its market position. GRAIL continues to push the boundaries of cancer diagnostics, striving to improve patient outcomes and revolutionise the way cancer is detected and treated.
DitchCarbon Score
How does GRAIL, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GRAIL, Inc.'s score of 23 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GRAIL, Inc.'s reported carbon emissions
GRAIL, Inc., headquartered in the United States, has made significant commitments towards reducing its carbon emissions, although specific emissions data is currently unavailable. The company is committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which GRAIL has officially joined, indicating a robust approach to climate action. As of 2023, GRAIL has set a near-term target status of "Committed," demonstrating its dedication to addressing climate change proactively. The pharmaceutical and biotechnology sector, in which GRAIL operates, is increasingly focused on sustainability, and the company is positioning itself to meet industry standards for emissions reductions. While specific reduction targets or achievements have not been disclosed, GRAIL's commitment to net-zero emissions reflects a growing trend among corporations to take responsibility for their environmental impact. The company’s initiatives are crucial in the context of global efforts to mitigate climate change and reduce greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GRAIL, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
